RaySearch Laboratories AB (publ)
RSLBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 16.6% | 21.2% | 31.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 91.7% | 89.6% | 88.7% | 92.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 21.9% | 11.2% | 5.1% | -8.2% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 17.1% | 8% | 2.8% | -7.4% |
| EPS | 5.94 | 2.38 | 0.69 | -1.38 |
| % Growth | 149.6% | 244.9% | 150% | – |
| EPS Diluted | 5.94 | 2.38 | 0.69 | -1.38 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 47.9% | 39.7% | 40.4% | 30.8% |